Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Shaojie Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7082-9573; OpenAlex author ID A5100623657. Sources: OpenAlex.

Their work

Papers
19
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. UBE3A-mediated mH2A1 Ubiquitination activates TERT transcription to promote senescence resistance in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08480-z↗
  2. DTL promotes pancreatic cancer progression through ubiquitin-mediated degradation of SMAD4. Co-author DOI 10.1016/j.ijbiomac.2025.148692↗
  3. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target. Co-author DOI 10.1007/s00432-024-05644-2↗
  4. Glycolysis and tumor progression promoted by the m6A writer VIRMA via m6A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216840↗
  5. Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02880-8↗
  6. A study on the role of Taxifolin in inducing apoptosis of pancreatic cancer cells: screening results using weighted gene co-expression network analysis. Co-author DOI 10.18632/aging.205500↗
  7. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Co-author DOI 10.1016/j.phrs.2022.106555↗
  8. Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1186/s13014-023-02273-w↗
  9. Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia… Co-author DOI 10.1039/d2bm01039a↗
  10. A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194722↗
  11. GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network. Co-author DOI 10.7150/jca.72161↗
  12. Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer. Co-author DOI 10.21037/tcr-21-980↗
  13. Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer. Co-author DOI 10.3389/fgene.2021.632803↗
  14. Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Co-author DOI 10.1007/s10637-019-00791-7↗
  15. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8. Co-author DOI 10.1002/cam4.1824↗
  16. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Co-author DOI 10.1002/ijc.31248↗
  17. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Co-author DOI 10.7150/thno.24281↗
  18. Pancreatic Cancer Epidemiology, Detection, and Management. Co-author DOI 10.1155/2016/8962321↗
  19. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy. Co-author DOI 10.1166/jbn.2016.2269↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaihong Huang · 15 shared papers, 2016–2024 · strength 1.90
  2. Yaqing Li · 13 shared papers, 2016–2024 · strength 1.71
  3. Guoda Lian · 13 shared papers, 2016–2024 · strength 1.59
  4. Likun Ren · 4 shared papers, 2024–2026 · strength 1.00
  5. Jinmao Zou · 5 shared papers, 2022–2024 · strength 0.88
  6. Shurui Zhou · 5 shared papers, 2022–2024 · strength 0.82
  7. Kege Yang · 7 shared papers, 2016–2024 · strength 0.78
  8. Jiajia Li · 6 shared papers, 2016–2024 · strength 0.76
  9. Xiaobin Fei · 3 shared papers, 2024–2026 · strength 0.76
  10. Yaozhen Pan · 3 shared papers, 2024–2025 · strength 0.71
  11. Yinting Chen · 7 shared papers, 2016–2021 · strength 0.62
  12. Shangxiang Chen · 4 shared papers, 2021–2023 · strength 0.58
  13. Yue Zhao · 3 shared papers, 2022–2024 · strength 0.55
  14. Ziyi Zhong · 3 shared papers, 2022–2024 · strength 0.54
  15. Linjuan Zeng · 5 shared papers, 2016–2018 · strength 0.35
  16. Yunlong Li · 2 shared papers, 2022–2024 · strength 0.34
  17. Yuzhou Huang · 2 shared papers, 2022–2023 · strength 0.32
  18. Hanming Yao · 2 shared papers, 2022–2023 · strength 0.31
  19. Rishang Lu · 1 shared paper, 2026 · strength 0.29
  20. Yaozhen Pan · 1 shared paper, 2026 · strength 0.29
  21. Fengjiao Li · 2 shared papers, 2022–2023 · strength 0.29
  22. Qiubo Zhang · 3 shared papers, 2016–2020 · strength 0.25
  23. Xi-zhuang Pan · 1 shared paper, 2025 · strength 0.25
  24. Peng Liu · 1 shared paper, 2024 · strength 0.23
  25. Chumei Huang · 3 shared papers, 2018 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.